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Abstract
Purpose To explore the effects of pegvisomant (PEGV) on glucose metabolism in patients with acromegaly within
ACROSTUDY, an international, observational, prospective safety surveillance study.
Methods Patients were retrospectively divided into two cohorts, with (DM group) or without diabetes mellitus (no-DM).
Parameters of glucose metabolism and IGF-I values were analyzed yearly both cross-sectionally for 4 years (yrs) and
longitudinally at 1 and 4–5 yrs of PEGV treatment.
Results Among 1762 patients, 510 (28.9%) had DM before PEGV start. At cross-sectional analyses, in the DM group mean
blood glucose was 140.0 ± 58.7 mg/dl at baseline, 116.4 ± 44.8 mg/dl at year 1 and 120.0 ± 44.3 mg/dl at yr 4. Mean HbA1c
was 6.6 ± 1.2 % at yr 1 vs. 7.0 ± 1.4 % at baseline. HbA1c was above 6.5% in 61.9% at baseline and ranged from 45.4 to
53.8% at subsequent yearly time points. At the 4-yr longitudinal analysis, in the DM group (n= 109), mean blood glucose
decreased by 20.2 mg/dl at yr 4, mean HbA1c was 7.0 ± 1.5% at baseline vs. 6.8 ± 1.4%. Patients achieved IGF-I nor-
malization in 52.1% and 57.4% of cases in the DM and no-DM groups, respectively at 1 year. The mean daily PEGV dose
(mg/day) was higher in the DM group (18.2 vs. 15.3) while the absolute change of IGF-I values from baseline was similar in
both groups. PEGV was well tolerated in both groups without any unexpected AEs.
Conclusions Patients with DM had a moderate decrease in mean fasting glucose values during PEGV treatment.
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Introduction
Growth hormone (GH) has anabolic effects, but also
antagonizes insulin actions as it stimulates lipolysis, glu-
coneogenesis, and glycogenolysis [1, 2]. Acromegaly is
almost always caused by pathological hypersecretion of GH
by a somatotropinoma of the anterior pituitary [3, 4]. Thus,
uncontrolled patients with acromegaly frequently have
diabetes, or at least impaired glucose tolerance (IGT), as
reported decades ago [5] and conﬁrmed by more recent
studies like the Liege Acromegaly Survey where 27.5% of
patients had diabetes mellitus (DM) at the time of their
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diagnosis [6]. Medical treatment modalities for acromegaly
may in turn reduce insulin resistance and increase insulin
sensitivity [7]. These treatments include somatostatin ana-
logues (SSAs), dopamine agonists, and the GH-receptor
(GHR) antagonist pegvisomant (PEGV) [3]. In a meta-
analysis, it was reported that classically used SSAs
(octreotide and lanreotide) may have a marginal negative
clinical impact on glucose homeostasis in acromegaly [8]
while in a head-to-head study vs. octreotide,
hyperglycemia-related adverse events (AEs) were more
common with long-acting pasireotide, a SSA targeting a
broader range of somatostatin receptor subtypes [9]. How-
ever, the mode of action of SSAs is complex as they have
direct and indirect effects on glycemic control, regardless of
GH and IGF-I [10, 11]. PEGV is the only GHR antagonist
available; it is a competitive blocker that competes with
endogenous GH for binding to the GHR [12–14]. Com-
pared to SSA treatment, PEGV appears to be superior in
improving glycemic control during the treatment of acro-
megaly patients [15, 16], and it has been shown to improve
peripheral and hepatic insulin sensitivity in acromegaly [17,
18].
Established in 2004, ACROSTUDY™ is a global safety
surveillance study of long-term PEGV treatment in acro-
megaly patients [19]. The objective of the present analysis
was to explore the effects of PEGV on glucose metabolism
parameters in patients enrolled in ACROSTUDY, according
to their initial diabetes or non-diabetes status.
Patients and methods
Study protocol
ACROSTUDY is an ongoing open-label, international, non-
interventional, post-marketing surveillance study open to
patients with acromegaly who are treated with (or about to
begin) PEGV. It is designed to monitor long-term safety and
outcomes in routine clinical practice. Since this is a non-
interventional study, treatment dosing regimen, as well as
timing of follow-up visits, pituitary imaging, and laboratory
evaluations are at the discretion of each treating physician/
investigator [19].
The most important exclusion criteria are: participation
in any clinical trial of an investigational drug for acrome-
galy, requirement for surgical decompression of the tumor
(such as in contact with the optic chiasm) or non-medical
therapy because of visual ﬁeld loss, cranial nerve palsies, or
intracranial hypertension. No speciﬁc additional diagnostic
or monitoring procedures must be conducted as part of this
study as previously reported [19]. The ACROSTUDY data
reported here were collected in compliance with, and
consistent with the most recent version of the Declaration of
Helsinki. In addition, all applicable local laws and reg-
ulatory requirements in the countries involved were adhered
to. Local ethical approval was obtained for all participating
centers and all patients provided written informed consent
prior to enrollment in the study.
Diabetes and no-diabetes groups
We investigated parameters of glucose metabolism in
patients followed in ACROSTUDY, using the database
freeze performed on December 4th, 2012. Two cohorts, DM
and no-diabetes (No-DM) were retrospectively identiﬁed.
Presence of DM was determined on previous medical his-
tory, or on the basis of the following criteria: HbA1c ≥
6.5%, or glucose >200 mg/dl as deﬁned by American Dia-
betes Association (ADA) guidelines [20], or antidiabetic
medication before PEGV start. IGT was deﬁned using the
same guidelines. Both cohorts were analyzed in a cross-
sectional manner at yearly time points for 4 years and in a
longitudinal manner 1 year and at least 4 years after PEGV
start. For the longitudinal analysis, values obtained between
4 and 5 years were considered as 4-year data. Main
demographic and anthropometric data, characteristics of
PEGV administration, HbA1c, IGF-I at PEGV start, pre-
vious treatments for acromegaly, concomitant treatments for
diabetes, and AEs were analyzed.
Concomitant therapies
Treatment for diabetes was classiﬁed into 3 categories:
category 1 included lifestyle measures only or in combi-
nation with metformin and/or acarbose; category 2 inclu-
ded any other oral antidiabetic agent or glucagon-like
peptide 1 (GLP1) analogs; category 3 comprised any form
of insulin treatment. Concomitant medications for acro-
megaly were evaluated to differentiate patients who were
on PEGV only (monotherapy group) and those who
received a combination (combination therapy group) of
PEGV and SSAs and/or dopamine agonists (DA). For
monotherapy, SSAs or DAs had to be stopped before or the
same day as PEGV treatment was initiated for the baseline
visit; at yearly visits, any SSA/DA treatment had to be
stopped at least 4 months/2 months before the yearly IGF-I
measurement. In the combination therapy group, at base-
line, SSA and/or DA should be given continuously, or with
a maximal gap of 6 weeks before the start of PEGV for
long-acting SSA and 30 days for short-acting SSA and DA;
at yearly visits, SSA and/or DA should be given con-
tinuously, or with a maximal gap of 6 weeks before the
yearly IGF-I measurement for long-acting SSA and 30 days
for short-acting SSA and DA.
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Laboratory tests and MRI evaluations
Hormonal and biochemical tests were realized at investi-
gator’s discretion, using commercial assays available in
each center, and interpreted according to the corresponding
normal reference ranges. IGF-I data were reported in rela-
tion to local reference values. The IGF-I values were also
expressed as percentage of the upper limit of age-adjusted
normal values.
The protocol recommended that the local MRI proce-
dures use the same imaging technique and equipment
whenever possible throughout ACROSTUDY, namely T1
weighted spin-echo (or fast spin echo) sagittal and coronal
images before and after gadolinium, and T2 weighted fast
spin echo coronal images. If the local radiologist reported a
signiﬁcant change in pituitary tumor size, whether it was
considered clinically important or not, all available images
for that patient were to be considered for central assessment
as previously described [19].
Safety evaluations
Comorbidities including DM, hypertension, cardiovascular,
and cerebrovascular diseases, respiratory tract disorders,
osteoarthritis, benign, and malignant tumors, sleep apnea,
and hepatic diseases, diagnosed before PEGV start were to
be reported at study entry. Safety was evaluated by col-
lection of AEs, serious adverse events (SAEs) and labora-
tory and MRI data as reported by investigators. For patients
treated with PEGV before entering ACROSTUDY, AE
collected prior to study entry were considered to be part of
the medical history and reported in the database if deemed
relevant. Any aggravation of a pre-existing condition during
ACROSTUDY was to be reported as an AE. In addition to
the analysis of new-onset DM reported as an AE, we also
considered all patients who did not meet the criteria for
diabetes as deﬁned above at the start of the study but did so
at any time point through the latest evaluation as developing
DM and regarded them as a new onset DM.
Statistical methods
All analyses were planned as descriptive summaries. The
full analysis set consisted of all subjects who entered
ACROSTUDY and received at least 1 dose of PEGV.
Baseline was deﬁned as the start of PEGV treatment,
regardless of the date of enrollment into ACROSTUDY. All
available data following PEGV start were to be
summarized.
For testing differences in laboratory data between DM
and no-DM patients, multiple regression analyses control-
ling for gender and age were used. The baseline test of age
and BMI between the groups was performed using
Wilcoxon rank test. For frequency tables Fischer’s exact test
was used for 2 × 2 tables and a chi-square test otherwise.
Correlation analyses were performed with Pearson correla-
tion coefﬁcients to analyze linear relationships between
variations in IGF-I and variations in blood glucose. Mc
Nemar’s test on paired nominal data was used to assess
change between two-time points in the prevalence of
patients with impaired glucose tolerance. P < 0.05 was
considered signiﬁcant. SAS® version 9.2 for Sun Solarix
(SAS Institute, Cary, North Carolina), Proc GLM, Proc
NPAR1WAY, Proc CORR, and Proc FREQ, was used for
the different statistical analyses.
Results
Baseline characteristics and demographic data
Patients were included from 15 countries in Europe and
North America (Table 1). A large majority (92.7%) was
Caucasian. The overall study cohort consisted of 1762
patients (892 males), of whom 510 (28.9%) were included
in the DM group and 1252 in the no-DM group. The
diagnosis of DM was based on the ADA-derived deﬁnition
of diabetes as an associated comorbidity at baseline in 485
patients, on an HbA1c value ≥6.5% in 11 patients, and on
the presence of an antidiabetic drug among concomitant
medications in 14 patients. There was a large variability in
the reported rate of DM within countries, ranging from
16.7% (Great Britain) to 56.6% (Greece). Main patients’
clinical and demographic characteristics at baseline are
summarized in Table 2. There was a signiﬁcantly greater
proportion of female patients in the DM group. Patients
Table 1 Distribution of patients among participating countries
Country Number of patients (%)
Germany 480 (27.2)
Italy 340 (19.3)
France 276 (15.7)
Spain 199 (11.3)
USA 120 (6.8)
Netherlands 108 (6.1)
Greece 53 (3.0)
Great Britain 48 (2.7)
Sweden 37 (2.1)
Denmark 32 (1.8)
Belgium 28 (1.6)
Slovakia 23 (1.3)
Portugal 9 (0.5)
Hungary 7 (0.4)
Austria 2 (0.1)
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with DM were signiﬁcantly older than those without DM at
diagnosis of acromegaly, and this still held true at the time
of PEGV start. As expected, patients with DM had a greater
BMI than those without DM.
As shown in Table 3, most patients had received surgical
and medical treatments for acromegaly before PEGV start,
and only 16.3% had received medical treatment only.
The median duration of acromegaly before PEGV start was
similar in DM and no-DM groups (4.7 and 4.1 years respec-
tively). Mean duration of PEGV treatment was also similar in
both groups (5.2 ± 2.7 yr vs. 5.4 ± 2.7 yr, respectively).
Cross-sectional analysis
As shown on Fig. 1a, the cross-sectional analysis showed
that fasting blood glucose values remained stable in the no-
DM cohort throughout the follow-up period whereas in the
DM group they decreased from 140.0 ± 57.8 mg/dl at
baseline to 116.4 ± 44.8 mg/dl (p= 0.0001) at year 1, and
120.0 ± 44.3 mg/dl at year 4 (p= 0.0001) In parallel, as
shown on Fig. 1b, HbA1c remained stable in the no-DM
group. In the DM group, HbA1c was above 6.5% in 61.9%
(161/260) of patients at baseline, 45.4% (114/251) at year 1
(p= 0.007) and 47.1–53.8% of patients at subsequent
yearly time points over 4 years. Prevalence of IGT
decreased from 11.2% at pegvisomant start to 8.0% at year
1, and 6.4% at year 4.
Between baseline and yearly evaluations, the proportion
of patients with normalized IGF-I increased from 16.1% to
52.6–58.9% in the DM group, and from 12.4% to
60.8–62.0% in the no-DM group (NS).
In patients with increased IGF-I, PEGV dose was 16.4 ±
9.3 mg vs 14.7 ± 7.8 mg in DM vs non-DM groups,
respectively at yr. 1, and 19.9 ± 11.4 mg vs 18.8 ± 9.3 mg at
yr. 4 (for both, p= 0.00006).
Longitudinal analyses
Analysis at 1 year
At year 1, in the patients for whom baseline and 1-year
follow-up data were available, blood glucose changed from
a mean of 132.8 ± 50.2 mg/dl to 116.5 ± 41.1 mg/dl in the
DM group (n= 141) and from 95.7 ± 16.4 to 90.6 ±
17.1 mg/dl in the no-DM group (n= 210). The decrease
was signiﬁcantly more pronounced in the DM group (p <
0.0001). Similarly, the decrease in HbA1c values was sig-
niﬁcantly more marked in the DM group (p < 0.05), where it
changed from a mean of 7.0 ± 1.5% to 6.6 ± 1.2% (n= 149)
compared to a change from 5.7 ± 0.45% to 5.5 ± 0.45% in
the no-DM group (n= 83).
Table 2 Baseline characteristics and demographic data
Variable, unit Diabetes
(n= 510)
No-diabetes
(n= 1,252)
P-value
Age at diagnosis, y 46.7 ± 13.45 39.7 ± 12.93 0.0001
Sex: M/F (%) 219/291 (43/57) 673/579 (54/46) 0.0001
Weight, kg 89.2 ± 19.12 87.4 ± 19.85 NA
Height, cm 168.7 ± 10.96 173.0 ± 11.70 NA
BMI, kg/m2 31.2 ± 6.00 28.6 ± 5.00 0.0001
Age at PEGV start, y 55.4 ± 13.47 49.1 ± 13.75 0.0001
Cause of GH hypersecretion (%)
Microadenoma 40 (8) 61 (5)
Macroadenoma 170 (34) 439 (36)
Pituitary adenoma (not speciﬁed) 288 (57) 719 (59)
Extrapituitary 1 (0.2) 3 (0.2)
Not known 3 (0.6) 7 (0.6)
Hypertension (%)
Yes 347 (68.7) 472 (40.2) 0.0001
No 158 (31.2) 703 (59.8) 0.0001
CVD (%)
Yes 364 (71.4) 513 (41) 0.0001
No 141 (27.7) 672 (53.7) 0.0001
Hyperlipidemia, n (%) 48 (9.4) 71 (5.6) 0.0045
IGF-I > ULN, n (% of patients
with available samples)
281 (83.1) 672 (85.8) NS
Data are mean ± SD or a proportion (%)
CVD cardiovascular disease (includes any cardiovascular comorbid-
ity), NS not signiﬁcant, NA not applicable
Table 3 Treatments before
pegvisomant start
Diabetes
(n= 510)
No-diabetes
(n= 1,252)
All (n= 1,762) P-value
Medical treatment only 103 (20.2%) 185 (14.8%) 288 (16.3%) < 0.01
Surgery only 21 (4.1%) 50 (4.0%) 71 (4.0%) NS
Radiotherapy only 0 1 (0.1%) 1 (0.1%) NA
Medical treatment and surgery 212 (41.6%) 626 (50.0%) 838 (47.6%) < 0.01
Medical treatment and radiotherapy 16 (3.1%) 24 (1.9%) 40 (2.3%) NS
Surgery and radiotherapy 12 (2.4%) 21 (1.7%) 33 (1.9%) NS
Medical treatment, surgery and
radiotherapy
126 (24.7%) 293 (23.4%) 419 (23.8%) NS
NA not available, NS not signiﬁcant
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In patients with elevated IGF-I levels at baseline, 52.1%
(100/192) in the DM group, and 57.4% (283/493) in the no-
DM group had normalized IGF-I levels at year 1, a differ-
ence that was not signiﬁcant. However, to achieve normal
IGF-I levels, DM patients had received a higher mean
PEGV dose (18.2 mg/day vs. 15.3 mg/day for no-DM
patients, p= 0.015).
Interestingly, we found that one year after pegviso-
mant start, there was a signiﬁcant correlation between
the delta IGF-I (n= 274) and delta glucose (n= 272), in
the whole cohort, with a linear correlation coefﬁcient r
= 0.21 (p= 0.0008), as well as in both the DM and no-
DM groups (r= 0.27; p= 0.007, and r= 0.20; p= 0.01,
respectively).
Analysis at 4 years
Mean glucose levels changed from 136.3 ± 49.9 mg/dl at
baseline to 116.1 ± 39.2 mg/dl at year 4 in the DM group (n
= 109, mean decrease of 20.2 mg/dl) and from 94.3 ±
20.2 mg/dl to 90.5 ± 15.2 mg/dl in the no-DM group (n=
142, mean decrease of 3.9 mg/dl), (p < 0.0001) (Fig. 2a). In
127 DM patients with available values, HbA1c changed by
0.13 ± 1.5%, from 7.0 ± 1.4% to 6.8 ± 1.4% (NS) (Fig. 2b).
HbA1c remained stable (data not shown) in the few no-DM
patients in whom this value was determined. Among
patients with elevated IGF-I at baseline, 53.0% (70/132) in
the DM group, and 59.1% (201/340) in the no-DM group
achieved normalization (NS). Four years after pegvisomant
start, there was no signiﬁcant correlation between the
decrease in IGF-I and the change in glucose.
Changes in diabetes treatment status
Changes in DM treatment groups from PEGV start to last
observation available (6 months to 4 years) are shown in
Table 4 (cross-sectional analyses) and Fig. 3a (in the
monotherapy group) and 3B (in the combination therapy
group) for the longitudinal analyses. Overall, most of DM
patients (87.2%) remained in the same group, while 4.1%
and 8.7% changed to a less intensive or more intensive
treatment category, respectively. Association of SSAs did
not signiﬁcantly affect treatment group allocation: in the
monotherapy and the combination therapy groups, 89.1%
and 85.0% remained in the same anti-diabetes treatment
category while 7.0% and 10.6%, changed to a more inten-
sive treatment group respectively.
Safety evaluations
Table 5 summarizes all-cause and treatment-related AEs in
the study population. The most common treatment-related
AEs were general disorders and administration site condi-
tions (1.8% in the DM cohort vs. 2.2% in the no-DM
group), nervous system disorders (1.4% vs. 1.5%), gastro-
intestinal disorders (1.2% in the DM cohort), and skin and
subcutaneous tissue disorders in the no-DM cohort (1.4%).
Treatment-related liver test abnormalities were reported in
12 (2.4%) DM and in 50 (4.0%) no-DM patients. There
were 18 (3.5%) and 24 (1.9%)—deaths (all-cause) in the
DM and no-DM cohorts, respectively. None were con-
sidered treatment-related by the investigator. In the DM
group, 36 patients (7.1%) withdrew study drug (temporarily
or permanently) due to—SAEs (all-cause). In the no-DM
group, drug withdrawal due to—SAEs (all-cause) occurred
in 55 patients (4.4%).
New onset DM was reported as an AE in 19 patients
during the period of observation. At the time point when
DM was reported as an AE, 8 patients were on pegvisomant
monotherapy and 11 patients were on combination therapy.
Among patients with no DM at PEGV start, we identiﬁed
—whether diabetes had been declared as an AE or not—those
Fig. 1 Cross-sectional analyses in patients with acromegaly treated with pegvisomant: Blood Glucose levels a and HbA1c b over time (yearly
evaluations)
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having at least one value of HbA1c and/or blood glucose
above the cut-offs and/or start of an anti-diabetes drug during
PEVG therapy. In total 82 fulﬁlled at least one of these criteria
(49 HbA1c, 46 anti-diabetes drugs, 9 blood glucose values).
There was no reported case of hypoglycemia in the DM
group and one case of hypoglycemia occurred in a 78-year
old female patient from the non-DM group, 1 year after
pegvisomant start.
Discussion
We described here the effects of PEGV therapy on glucose
metabolism in acromegaly patients enrolled in ACROS-
TUDY. This population mainly consists of patients in
whom previous medical treatments failed to control acro-
megaly. Nevertheless, they seem to be representative of
acromegaly patients described in several previous series, as
regards age at diagnosis and characteristics of the disease
[6, 21–25]. Previous ACROSTUDY reports have shown
that undertreatment remains a major issue in daily clinical
practice, highlighting the value of real-world data, and that
inadequate control of acromegaly represents a risk factor for
persistently altered glucose metabolism (19). This is con-
ﬁrmed by our present results showing that, one year after
pegvisomant start, there was a signiﬁcant correlation
between delta IGF-I and delta glucose, in both DM and no-
DM groups. This suggests that correction of IGF-1 excess
by antagonizing GH-receptor activity (rather than a direct
effect of the drug) is likely to account for the outcome of
glucose parameters in treated patients.
Prevalence of diabetes
We observed in our cohort that the prevalence of diabetes
was very different among countries. This ﬁnding is con-
sistent with data from national registries [21–25]. In the
German Pegvisomant Observational Study (GPOS), it was
37.6%, compared to 6.9% in a control group, representative
of the general population [26]. Interestingly, the Liege
Acromegaly Survey, based on 3173 patients [6], noted a
signiﬁcant relationship between glucose levels and IGF-1
concentrations. DM has indeed been shown to be correlated
with high IGF-I levels [6, 20, 26, 27], but not with GH
levels [21, 28, 29]. We did not observe this ﬁnding in our
study but it was noted that, as in many other series, DM was
associated with older age [21, 22, 25, 27, 28], and higher
BMI [25, 27, 28]. Yet, DM carries overall poorer prognosis,
with increased mortality in acromegaly patients [22, 30].
Effects of treatments on glucose metabolism
Impaired glucose metabolism in acromegaly is mainly due
to insulin resistance, resulting from chronic excessive GH
Fig. 2 Longitudinal analyses in patients with acromegaly treated with pegvisomant: Blood Glucose levels a and HbA1c b over time (yearly
evaluations)
Table 4 Cross-sectional analysis of antidiabetic treatments in patients
with DM receiving pegvisomant monotherapy or combination therapy
DM treatment
category
Baseline
n= 429
Year 1
n= 322
Year 4
n= 277
All Patients, n (%) 1 244 (57) 143 (44) 104 (37)
2 49 (11) 70 (22) 66 (24)
3 136 (32) 109 (34) 108 (39)
PEGV monotherapy 1 117 (60) 56 (43) 43 (36)
2 23 (12) 31 (24) 28 (24)
3 56 (28) 44 (36) 47 (40)
Combination therapy
PEGV+ SSA
1 79 (53) 58 (48) 38 (38)
2 18 (12) 21 (17) 26 (26)
3 51 (34) 41 (34) 35 (35)
1: Lifestyle intervention with or w/o metformin/acarbose, 2: Addition
of any other kind of therapy except insulin, 3: Insulin with any other
therapy
PEGV pegvisomant, SSA somatostatin analogues
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exposure. Therefore, any treatment that normalizes GH/
IGF-I should improve insulin sensitivity and decrease glu-
cose intolerance, provided that the treatment does not also
decrease insulin secretion as well, as is the case with SSAs.
Therefore, the results with SSAs are more nuanced:
although they can improve glucose parameters by reducing
GH/IGF-I concentrations, they may also impair glucose
tolerance because of complex interactions between soma-
tostatin receptors and glucose regulatory hormones, and
inhibition of beta cells secretory functions [7, 31]. The
beneﬁts of treatment on glucose metabolism have been
clearly demonstrated for surgery [32].
In a study by Colao et al., 100 patients treated with
surgery only, SSAs only or both presented with deteriora-
tion of glucose tolerance after 60 months [33]. Another
study on 45 de novo patients with a 5-year ﬁrst-line
treatment with SSA concluded that the prevalence of IGT
and DM did not change signiﬁcantly during this period [34].
Glucose metabolism was also investigated in 51 patients,
among which 18 were treated with lanreotide autogel and
33 had no medical treatment [35]. Differences were shown
between groups: HOMA-R was similar in both but HOMA-
β was signiﬁcantly lower in treated patients, suggesting that
SSAs decrease β-cell function but do not affect insulin
resistance [35]. The multireceptor-targeted SSA pasireotide
was found in healthy volunteers to increase glucose levels,
while hepatic and peripheral insulin sensitivity remained
unchanged [36]. In medically naïve patients with acrome-
galy, pasireotide was compared to octreotide in a pro-
spective randomized double-blind study, and resulted in
higher rates of hyperglycemia-related events (57.3% vs
21.7%) [9].
In contrast, glucose metabolism improves on PEGV, as
shown in our series, with a signiﬁcant decrease in mean
glucose levels in DM patients while they remained stable in
no-DM patients. We also observed a signiﬁcant decrease in
the proportion of patients with IGT from 11.2% at pegvi-
somant start to 6.4% at year 4. However, in the context of
an observational study not designed to address any efﬁcacy
endpoint—and due to a substantial proportion of missing
data especially on glucose metabolism—the decrease in
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Fig. 3 Change in DM treatment from PEGV start to last observation (6 months to 4 years) in the pegvisomant (PEGV) monotherapy group a, and
in the combination group b: longitudinal analyses in 129 patients
Table 5 Summary of all-cause and treatment-emergent adverse events
(AEs) and serious AE (SAEs)
N Patients
with
AEs, n
Treatment-
emergent
AEs, n
Patients
with
SAEs, n
Treatment-
emergent
SAEs, n
Diabetes 510 258 965 (95) 76 194 (12)
No-diabetes 1252 568 2094 (305) 125 368 (30)
Total 1762 826 3059 (400) 201 562 (42)
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HbA1c was not statistically signiﬁcant. These effects are
probably mediated by an increased insulin sensitivity,
which in turn lowers glucose levels and reduces beta-cell
stimulation, and eventually restores insulin response to
glucose exposure [37], as shown by previous studies [17].
This is unlikely to be attributable to a direct antidiabetic
effect of the drug but may rather be due to an indirect effect
due to the decreased activation of GH receptors secondarily
resulting in improved insulin sensitivity. Similarly, Barkan
et al showed that patients switched from octreotide LAR to
PEGV had decreased glucose and HbA1c levels after
32 weeks, whether patients were diabetic or not at the start
of treatment [15]. In a study with sequential treatment (SSA,
followed by no treatment, then PEGV then SSA+ PEGV),
performed in 11 patients refractory to SSA alone [37],
glucose levels were the lowest during PEGV therapy and
the highest during SSA treatment, intermediate values being
reported during combined treatment.
In the ﬁrst large cohort of patients published in 2001 by
Van der Lely et al., patients had a decrease in fasting insulin
and fasting glucose while HbA1c did not change sig-
niﬁcantly [38]. In the German ACROSTUDY cohort [39],
the mean duration of PEGV was 174 weeks, 70% of
patients received monotherapy while the remaining 30%
had combined treatment (PEGV+ SSA). In the whole
group of DM patients with available data, the decrease in
HbA1c was statistically signiﬁcant but a sub-group analysis
showed that it remained signiﬁcant only in the monotherapy
group although the IGF-I response was of the same order of
magnitude. In our cohort, almost 90% of DM patients
remained in the same antidiabetic treatment category. We
could not ﬁnd differences between those receiving PEGV
monotherapy and those with combined treatment (PEGV+
SSA). However, these data were collected at different time
points, and in a limited number of patients, which is prob-
ably insufﬁcient to show differences if any. Of note, the
present study was not designed to compare the respective
effects of PEGV and SSA alone or in combination on
glucose metabolism.
Other treatment effects
In our cohort, the efﬁcacy of PEGV appeared similar in DM
and no-DM patients, since the proportions of those who
normalized IGF-I were the same in both groups. However,
in patients with normal IGF-I levels after 1 year, the mean
PEGV dose was higher in DM than in no-DM patients
(18.2 mg/d vs 15.3 mg/d, p= 0.015). In the German
ACROSTUDY cohort, patients with DM achieved IGF-I
normalization less frequently than non-diabetic ones, but
they also required higher PEGV doses to normalize IGF-I
(18.9 vs 15.5 mg/day, p < 0.01). This difference was even
more pronounced in patients treated with insulin (22.8 vs
17.2 mg/day for those treated with oral antidiabetic drugs, p
= 0.11) [39]. This is in line with the concept that low
insulin levels in the portal circulation reduce IGF-I gen-
eration by the liver, while high portal insulin concentrations
increase the liver sensitivity for GH by increasing the
number of GHR at the hepatocytes’ surface [40]. The vast
majority of our DM patients had type 2 diabetes, thus
probably hyperinsulinemia and then, more GH receptors in
the liver [40]. Since PEGV is a competitive blocker, there is
a need for more drug to block GHRs when their number
increases, which probably explains the observed need for a
higher dose in the controlled DM patients than in the no-
DM group.
Limitations
This is a large observational/non-interventional study;
however, some parameters were not analyzed adequately,
due to missing data. Moreover, ACROSTUDY is not
designed to evaluate speciﬁcally glucose metabolism issues
and investigators may have focused more on acromegaly
data than on comorbidities, glucose tests, diabetes medica-
tions, or HbA1c. For this reason, some analyses are
restricted to a small percentage of the initial cohort. Fur-
thermore, the study did not allow a strict analysis of the role
of IGF-I control on the outcome of glucose metabolism.
Thus, the actual data are not sufﬁcient to distinguish
between a possible effect of pegvisomant on glucose
metabolism and an indirect effect through the normalization
of IGF-I. Likewise, we did not investigate the mechanisms
of glucose parameters changes by measuring insulin sensi-
tivity of beta-cell functions. Therefore, we did not perform
additional analyses to differentiate between patients
receiving PEGV monotherapy or combination therapy.
Conclusion
In this observational, international, surveillance study, we
demonstrated that PEGV can be used effectively and safely
in diabetes patients with acromegaly. The treatment resulted
in a moderate decrease in mean glucose levels. The efﬁcacy
was similar in diabetes and non-diabetes patients. The
safety proﬁle was similar in both groups, without any
unexpected adverse event. Due to these effects on glucose
metabolism, PEGV appears to be a favorable therapeutic
option in diabetes patients with acromegaly.
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